BioStock: Abliva’s CEO: ”Orphan drug designation is great validation”

Biotech Abliva enters the holiday period on a high note with the announcement that NV354 has received orphan designation from the European Commission. The candidate is being developed for treatment of mitochondrial disease with neurologic complications,  and the designation is expected to facilitate clinical development. BioStock reached out to Abliva’s CEO Ellen K. Donnelly for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2023/12/ablivas-ceo-orphan-drug-designation-is-great-validation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/